emergers.se https://validator.w3.org/feed/docs/rss2.html CRUNCHFISH Crunchfish: Chairman and CEO secure funding while strategic positioning continues to expand NANEXA: Funding secured as semaglutide pivot sharpens commercial focus NANEXA PROLIGHT: Pre-validation readout in Q4 sets stage for multicenter trial in 2025 News Home NANEXA: First license with Moderna an important validation of PharmaShell NANEXA AB: Positive clinical data balanced by strategic uncertainty about NEX-22 roadmap PROLIGHT: Fully subscribed rights issue strengthens Psyros case ahead of commercial partnerships PROLIGHT DIAGNOSTICS CINDRIGO CINDRIGO HOLDINGS: Powering Europe’s clean baseload transition with LSE listing and first revenues CRUNCHFISH: Breakthrough integration sets stage for commercial expansion NANEXA: Intensified focus on deals amid growing funding pressure PROLIGHT: Financing and partner interest strengthen case ahead of regulatory study CRUNCHFISH: Improved outlook with NPCI adoption and global validation PROLIGHT: Positive patient data and patent approval strengthen case for Psyros GRÄNGESBERG EXPLORATION PROLIGHT: Positive results from the pre-clinical validation study de-risk the full clinical validation NANEXA: Clinical milestones align ahead of phase Ib/II and licensing push CRUNCHFISH: Third time a charm? New offline strategy targets system integration QLUCORE PROLIGHT: Gearing up for commercialisation with strong insider backing CINDRIGO HOLDINGS: Lower risk with first revenues, Germany secured and LSE Main Market listing SIMRIS ALG NORTHERN CAPSEK VENTURES FREE2MOVE MOTION DISPLAY NANEXA: Targeting treatment of first patient in phase Ib/II with NEX-22 before year-end TALLINK: Free cash flow support dividends CRUNCHFISH: System-level positioning in place, commercial traction still pending AGTIRA GRANGEX: Steady progress in Norway, but new headwind in Sweden prompt additional patience from investors PROLIGHT: Commercial prototype marks an important milestone towards upcoming studies TALLINK NANEXA: Financing secured into 2026 to drive NEX-22 development CINDRIGO HOLDINGS: Lower risk with first revenues and LSE Main Market listing   PROLIGHT: SpinChip deal highlights the strategic importance and valuation potential of Prolight’s solution GRANGEX: PEA confirmns robust economics for Sydvaranger – mapping the road to financial close in H2’25 CRUNCHFISH: Detailing the eight revenue opportunities ahead PROLIGHT: Advancing with strengthened financials towards clinical performance study in 2025 NANEXA: Phase I results position NEX-22 for licensing opportunities and a head start in long-acting GLP-1 CRUNCHFISH: Still in the running for a one billion-user Digital Cash market NANEXA: Progress for rival at Novo illustrates the significant value potential in Nanexa CRUNCHFISH: Rights issue to stay the course on extended timeline GRANGEX: Emerging as Europe’s top DR concentrate developer MOTION DISPLAY: Strong gross margin driving another profitable quarter   CRUNCHFISH: Q3 report webinar TALLINK: All about the Dividend